IL18 and prostate carcinoma: A Mendelian randomization study, using GWAS summary data on 35 interleukins from large-scale proteomic studies across eight independent populations of European descent and data on 23 common cancers from the FinnGen Consortium, identified IL-18 as a risk factor for prostate cancer (91–93).